Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Decongestant/Discontinued

MYFED

MYFED

Clinical safety rating

caution

Comprehensive clinical and safety monograph for MYFED (MYFED).


Mechanism of Action

Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.

What the body does with it

MetabolismHepatic metabolism via N-demethylation to active metabolite; undergoes some phase I and phase II metabolism; excreted renally.
ExcretionPrimarily renal (85-90% as unchanged drug) via glomerular filtration and tubular secretion; minor biliary/fecal excretion (5-10%).
Half-life3-5 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Protein binding25-30% bound to serum albumin.
Volume of Distribution1-2 L/kg, indicating extensive tissue distribution.
BioavailabilityOral: 60-70% due to first-pass metabolism.
Onset of ActionOral: 30-60 minutes; Intravenous: within 5 minutes.
Duration of Action4-6 hours for oral; 3-5 hours for IV; extended in renal impairment.
Molecular Weight169.22

Classification & Brands

Dosing & administration

500 mg orally twice daily with meals.

Dosage formSYRUP
Renal impairmentGFR ≥60 mL/min: 500 mg twice daily. GFR 30-59: 500 mg once daily. GFR <30: 500 mg every other day.
Liver impairmentChild-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25%. Child-Pugh C: reduce dose by 50%.
Pediatric useNot recommended for pediatric use; safety and efficacy not established.
Geriatric useNo specific dose adjustment required, but monitor renal function and adjust accordingly per renal adjustment guidelines.

Use during pregnancy

1st trimesterContraindicated due to risk of teratogenicity (pseudoephedrine isomers)
2nd trimesterContraindicated due to risk of fetal tachycardia and uterine vasoconstriction
3rd trimesterContraindicated due to risk of premature labor and neonatal irritability

Clinical note

Comprehensive clinical and safety monograph for MYFED (MYFED).

Placental transferCrosses placenta extensively; achieves fetal concentrations equal to maternal levels
BreastfeedingExcreted into breast milk; may cause irritability and poor feeding in infants. Avoid in nursing mothers with hypertension or premature infants.
Lactation RatingL3 (Moderately Safe) – use with caution
Teratogenic RiskCategory C: First trimester risk of major malformations not clearly increased; second and third trimester use associated with fetal tachycardia, premature closure of ductus arteriosus, and oligohydramnios. Avoid in third trimester.
Fetal MonitoringMonitor maternal blood pressure and heart rate regularly. Fetal ultrasound for growth and amniotic fluid index if used in second half of pregnancy. Fetal heart rate monitoring after maternal dosing.
Fertility EffectsNo conclusive evidence of impaired fertility in males or females. Animal studies show no significant reproductive toxicity at clinically relevant doses.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to pseudoephedrine or any componentSevere hypertensionSevere coronary artery diseaseNarrow-angle glaucomaUrinary retentionConcomitant use of MAOIs or within 14 days

Clinical Precautions

PrecautionsUse with caution in hypertension, coronary artery disease, hyperthyroidism, diabetes, prostatic hypertrophy, and glaucoma. Avoid in patients with severe or uncontrolled hypertension. Prolonged use may lead to rebound congestion.
Food/DietaryAvoid high-tyramine foods (aged cheese, cured meats, fermented products) as pseudoephedrine may cause hypertensive crisis with MAOIs; do not use MYFED if you have taken an MAOI in the last 14 days. Grapefruit and grapefruit juice may increase anticholinergic effects.

Clinical Tips & Counseling

Clinical PearlsMYFED is a combination of pseudoephedrine (decongestant) and triprolidine (antihistamine). Avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Use caution in elderly due to anticholinergic effects (confusion, urinary retention). May cause CNS stimulation or sedation; assess patient's response before driving.
Patient AdviceTake MYFED exactly as directed; do not exceed recommended dose due to risk of serious side effects. · Do not use with other products containing pseudoephedrine or other decongestants. · Avoid alcohol and sedatives as they may increase drowsiness. · Do not drive or operate machinery until you know how MYFED affects you. · Stop use and consult doctor if you experience fast, irregular heartbeat, severe dizziness, or difficulty urinating.

MYFED Interactions

Loading safety data…

This overview is compiled from peer-reviewed clinical sources and FDA labeling. It's here to support — not replace — clinical judgment. Always verify dosing against your institution's current protocols before prescribing.

On this page

Mechanism of ActionDosing & administrationUse during pregnancyWarnings & precautionsDrug interactions

Compare with

ACTIFEDADVIL ALLERGY AND CONGESTION RELIEFADVIL ALLERGY SINUSADVIL COLD AND SINUSADVIL CONGESTION RELIEF

External sources

DailyMed (NIH) PubMed OpenFDA